CD&R and McKesson agree to acquire Option Care Health in $5.8 billion deal

CD&R and McKesson will acquire Option Care Health for $32.05 per share, valuing the company at $5.8 billion including debt. The deal, expected to close in early 2027, gives CD&R majority ownership and McKesson a 49% stake. Option Care's Q2 revenue rose 1.9% to $1.442 billion, with net income up 6.7% to $53.9 million.

Original reporting
Published Oct 6, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 2:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CD&R and McKesson agree to acquire Option Care Health in $5.8 billion deal — source image
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The transaction creates a vertically integrated platform for drug, equipment, and clinical support services, potentially improving margins but also adding execution risk.

02

Market read

The announcement is a material M&A event in the healthcare sector, likely moving Option Care shares sharply and prompting sector re‑valuation.

03

What to watch

Regulatory scrutiny of home infusion reimbursement could affect long‑term profitability.

Relevance 9/10Novelty 9/10Timing: announcement today

Background

The deal combines a private equity firm (CD&R) with a major healthcare distributor (McKesson) to acquire a leading home infusion provider.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health announced a $5.8 billion acquisition by CD&R and McKesson at $32.05 per share, a 37% premium to the prior close.

Expected impact

upward pressure as the market prices in the 37% premium

Evidence & confidence

The deal price is above market, providing immediate upside for shareholders.

$MCKNeutralMedium confidence
Context

McKesson will invest about $1.4 billion for a 49% stake in Option Care Health as part of the $5.8 billion transaction.

Expected impact

limited impact, likely flat to slight dip due to cash deployment

Evidence & confidence

The investment is sizable but does not directly affect McKesson's core earnings; market reaction may be muted.

Market effects

Consolidates the home infusion market, potentially prompting further M&A activity in healthcare services.

U.S. healthcare sector may see a modest uplift as investors reassess valuation of similar providers.

Highlights private equity's continued appetite for large-scale healthcare acquisitions worldwide.

Counterpoint

The premium may be excessive if integration costs rise, suggesting a possible overvaluation.

Key entities

  • CD&R

    Lead investor acquiring a controlling stake in Option Care Health.

  • Option Care Health

    Home infusion services provider being acquired.

  • McKesson

    Healthcare distributor taking a 49% stake in the transaction.

Related articles

$MCKHighAI 9/10

McKesson, private equity firm buy home infusion company, Option Care Health

McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.

$LWHighAI 8/10

US Stock Movers: Lamb Weston, Option Care, Apogee Rally

Lamb Weston (LW) shares rose 11.85% after reporting Q1 sales of $1.67B and raising 2027 EBITDA guidance. Option Care (OPCH) jumped 32.8% on a $5.8B take-private deal. Apogee (APOG) gained 18.7% on strong Q2 earnings and raised FY2027 outlook. Constellation (CEG) surged 14.79% after a Google nuclear deal. RPM (RPM) rose 2.5% on record Q1 results.

$MCKHighAI 9/10

McKesson, CD&R to Buy Option Care for $5.8B

McKesson Corp. and private equity firm Clayton, Dubilier & Rice will acquire Option Care Health Inc. for $5.8 billion, or $32.05 per share, a 37% premium. McKesson will own 49%, with CD&R as the controlling shareholder. Option Care, a major provider of home and outpatient infusion care, will retain its management team. The deal aligns with McKesson's strategy to expand specialty care services, potentially increasing its ownership over time.

$OPCHHighAI 9/10

Option Care Health (OPCH) Rockets as CD&R, McKesson Table 37% Premium Bid

Option Care Health (OPCH) surged 33% to $31.11 after announcing a $5.8B acquisition by CD&R and McKesson at a 37% premium. The deal, expected to close in 2027, values OPCH at $32.05 per share. The company will delist from Nasdaq. Hedge fund holdings fell 42% QoQ despite more funds establishing positions. Q3 earnings, due Nov 4, 2026, will not include guidance.

$OPCHMedAI 9/10

Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread - Option Care Health (NASDAQ:OPC

Option Care Health (OPCH) agreed to be taken private by Clayton Dubilier & Rice and McKesson (MCK) for $32.05 per share, valuing the company at $5.8B. Shares traded at $31.05, leaving a $1.00 spread. The deal is expected to close in H1 2027, subject to approvals. McKesson will invest $1.4B for a 49% stake, with an option to buy out CD&R later. OPCH shares rose 32.78% on the news.